Projected impact of 2026 ACC/AHA/Multisociety Dyslipidemia Guideline on lipid-lowering therapy eligibility based on Class 1 and 2a recommendations
Journal of Clinical Lipidology · 2026-09 · 20 (9) · 2046-2050
DOI: 10.1016/j.jacl.2026.07.008 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Clinical Lipidology, 2026-09. Verfasst von Sameer A Sidiq und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Baylor College of Medicine, Houston, TX, United States (Sidiq and Zhang). Electronic address: Sameer.Sidiq@bcm.edu. Hauptthemen laut MEDLINE: Dyslipidemias, American Heart Association, Practice Guidelines as Topic, Hypolipidemic Agents. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The 2026 American College of Cardiology/American Heart Association/Multisociety Dyslipidemia Guideline introduced pivotal changes to lipid-lowering therapy (LLT) eligibility compared with the 2018 Guideline. OBJECTIVE: We aimed to compare eligibility for Class 1 and 2a LLT indications in the United States between the 2018 and 2026 Dyslipidemia Guidelines. METHODS: We utilized National Health and Nutrition Examination Survey 2011-2018 datato evaluate LLT eligibility among participants aged ≥20 years, excluding pregnant women. Population weighted estimates were generated by indication and by demographic characteristic. RESULTS: Under the 2026 Guideline, 102.9 million adults (46.8%, 95% CI: 45.0-48.6) would be eligible for LLT, including 65.3 million (29.7%, 95% CI: 28.0-31.4) with a Class 1 indication and 37.6 million (17.1%, 95% CI: 15.8-18.4) with a Class 2a indication, compared with 65.3 million adults (29.7%, 95% CI: 28.1-31.3) under the 2018 Guideline, including 60.2 million (27.4%, 95% CI: 25.8-28.9) and 5.1 million (2.3%, 95% CI: 2.0-2.7), respectively. The increase in eligibility was primarily driven by 2 additional Class 2a indications introduced in the 2026 Guideline: individuals with borderline Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) risk (previously classified as Class 2b) and adults aged 30 to 59 years with low PREVENT risk but elevated low-density lipoprotein cholesterol or elevated 30-year atherosclerotic cardiovascular disease risk. CONCLUSION: Future studies should assess whether expanded eligibility improves LLT use and cardiovascular outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Baylor College of Medicine, Houston, TX, United States (Sidiq and Zhang). Electronic address: Sameer.Sidiq@bcm.edu.
- Department of Medicine, Baylor College of Medicine, Houston, TX, United States (Sidiq and Zhang).
- Division of Cardiovascular Medicine, Loma Linda University Medical Center, Loma Linda, CA, United States (Abramov).
- Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA, United States (Razavi).
- Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States (Nambi, Jia, Ballantyne, and Minhas); Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Hous…
- Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States (Nambi, Jia, Ballantyne, and Minhas).
Zitieren
APA
Sidiq, S. A., Zhang, G. Y., Abramov, D., Razavi, A. C., Nambi, V., Jia, X., Virani, S. S., Ballantyne, C. M., Blumenthal, R. S., & Minhas, A. M. K. (2026). Projected impact of 2026 ACC/AHA/Multisociety Dyslipidemia Guideline on lipid-lowering therapy eligibility based on Class 1 and 2a recommendations. Journal of Clinical Lipidology, 20(9), 2046-2050. https://doi.org/10.1016/j.jacl.2026.07.008
Vancouver
Sidiq SA, Zhang GY, Abramov D, Razavi AC, Nambi V, Jia X, et al. Projected impact of 2026 ACC/AHA/Multisociety Dyslipidemia Guideline on lipid-lowering therapy eligibility based on Class 1 and 2a recommendations. Journal of Clinical Lipidology. 2026;20(9):2046-2050. doi:10.1016/j.jacl.2026.07.008
BibTeX
@article{Sidiq2026,
author = {Sidiq, Sameer A and Zhang, Geoffrey Y and Abramov, Dmitry and Razavi, Alexander C and Nambi, Vijay and Jia, Xiaoming and Virani, Salim S and Ballantyne, Christie M and Blumenthal, Roger S and Minhas, Abdul Mannan Khan},
title = {Projected impact of 2026 ACC/AHA/Multisociety Dyslipidemia Guideline on lipid-lowering therapy eligibility based on Class 1 and 2a recommendations},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {9},
pages = {2046--2050},
doi = {10.1016/j.jacl.2026.07.008}
}
EUVIMED